#1INNOVATION WITH INTEGRITY Bruker Corporation Investor Day 2023 June 15, 2023 Focus on Proteomics and Spatial Biology BRUKER#2BRUKER CORPORATION 2023 INVESTOR DAY Safe Harbor Statement Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2023 financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, constant currency revenue growth, foreign currency translation revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; management's expectations for the impact of foreign currency and acquisitions, and for future financial and operational performance and business outlook; future economic conditions; the duration and impact of supply chain and geopolitical challenges; strategic investments; and statements found under the "Use of Non-GAAP Financial Measures" section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to COVID-19, the length and severity of any recession and the impact on global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from its ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, continued volatility in the capital markets, the impact of increased interest rates, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, the impact of foreign currency exchange rates, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2022, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. 2023 Bruker BRUKER Innovation with Integrity June 15, 2023 1#3BRUKER CORPORATION 2023 INVESTOR DAY Agenda 11:00 am to 1:30 pm EDT 01 Bruker Strategy - Proteomics & Spatial Frank H. Laukien, President & CEO 02 03 Proteomics Drug Discovery Services & Tools Oliver Rinner, President, Biognosys (Video) 04 2023 Bruker Unbiased, Deep 4D-Proteomics on timsTOF Rohan A. Thakur, President, Life Sciences MS (Video) Break 05 06 07 08 Spatial Biology and Cell Microscopy Mark Munch, President, Bruker NANO In-vivo Microscopy in Neuroscience Research Kunal Ghosh, CEO, Inscopix and Xiaomei Li, Bruker VP & GM, Fluorescence Microscopy (Video) Medium-Term Outlook 2026 Gerald Herman, Chief Financial Officer BRUKER Q&A Session Adjourn Innovation with Integrity | June 15, 2023 I#4INVESTOR DAY 2023 Bruker Strategy & Opportunities Focus on Proteomics & Spatial Biology Frank H. Laukien, Ph.D. Chairman, President & CEO BRUKER#5INVESTOR DAY 2023 Key takeaways of Investor Day 2023: Disciplined entrepreneurialism at work Project Accelerate 2.0 has transformed Bruker into a higher organic growth company Goal to grow revenue organically 200-300 bps above market in 2023-2026 Dual Strategy of Project Accelerate & Operational Excellence delivers solid margin expansion Goal to grow non-GAAP EPS in double digits in 2023-2026, with continued high RolC Bruker Management Process and culture of Disciplined Entrepreneurialism drive profitable growth Bruker investing to seize large secular opportunities in Proteomics and Spatial Biology timsTOF 4D-Proteomics is game-changing and drives unbiased proteomics ● ● ● 2023 Bruker BRUKER Innovation with Integrity | June 15, 2023 T 5 сл#6INVESTOR DAY 2023 Bruker at a Glance Leading provider of high-value life science tools and solutions ▪ #1 or #2 market position in majority of our portfolio Deep expertise in physics, chemistry, and biology Organic growth, innovation and high RolC philosophy ■ 2022 BSI (2) Markets Applied/Food Semi-Metrology 4% 10% Microbiology 10% BioPharma 16% Industrial & Green Tech 2023 Bruker 21% Academic & Government 39% Bruker Core >$2.8B(¹) Revenue 2022 Project Accelerate 2.0 PA 2.0 56% 10⁰ Project Accelerate 2.0 Drives Revenue Growth & Margins >8,500 Colleagues TIMI 30% Repositioned for Strong Secular Trends, Diversified Markets Mitigate Risk (1) 2023 guidance. (2) Bruker Scientific Instruments (BSI) revenue reflects sum of BSI BioSpin, BSI CALID and BSI Nano Segments 2022 BSI (2) by Geography BRUKER 34% R&D ~10% of Revenue 36% Balanced Mix, with Recent Rapid Growth in US Innovation with Integrity | June 15, 2023 1 6#7INVESTOR DAY 2023 Innovation with Integrity meets Disciplined Entrepreneurialism Mission: Customer Success Our high-performance scientific instruments, life science research and diagnostic solutions, and comprehensive support, enable our customers' discoveries and innovation, and drive their productivity and success. Driven by Purpose & Passion We are driven to make important contributions to the health, prosperity and safety of humankind. Via scientific, technological, diagnostic and business innovations, we create sustainable value for our customers, partners, colleagues and shareholders. 2023 Bruker BRUKER Y BRUKER Values: Integrity & Quality We value integrity, respect and trust within a fast-paced and dynamic environment built around scientific solutions. Ethical behavior, equal opportunity, inclusivity, compliance and commitment are at the heart of our business. Our Unique Culture We foster a diverse, high-performance culture of disciplined entrepreneurialism. We are caring, inclusive and people-oriented. We drive innovation, aim for breakthroughs, operate with discipline and good processes, all with passion and commitment. Innovation with Integrity | June 15, 2023 T 7#8■ ■ INVESTOR DAY 2023 Dual strategy of Project Accelerate 2.0 and Operational Excellence works Project Accelerate 2.0 Initiatives Pull up growth and margins Re-positioning Bruker for high-growth, high- margin opportunities Innovating to push envelope in sensitivity, resolution, quantification, throughput. Building unique, leading platforms for novel applications, life-science solutions Solving complex biology in large TAMs with strong secular growth ▪ Project Accelerate 2.0 at ~56% of revenue, with DD revenue CAGR 2023 Bruker Assays, Software & Aftermarket Next-gen Nano & Semi Tools Unbiased Proteomics & Multiomics BRUKER Biopharma & Applied Microbiology & Molecular Dx Spatial Biology, Single-Cell Omics, Cellular Analysis BRUKER Operational Excellence ▪ Pushes up market share, margins ▪ Cadence and control of Bruker Management Process drives execution and predictability ▪ Includes commercial and product R&D excellence ▪ Disciplined financial execution: significant investments and margin expansion, high ROIC ▪ Prudent capital allocation with conservative margin of safety Innovation with Integrity | June 15, 2023 I 8#9INVESTOR DAY 2023 Bruker transformation accelerates value-creation for all stakeholders ■ 2014-2016: RESTRUCTURING & TRANSFORMATION PHASE ■ Organic Revenue CAGR 8% 8% ■ 2% 2012-18 G = guidance midpoint ■ Cost out, consolidation and divestitures New organization & management process Integrated ERP, SF CRM adoption New HR compensation/incentives Increased outsourcing 2023 Bruker 2018-23G ■ 2017-2020: PROJECT ACCELERATE & OPERATIONAL EXCELLENCE ■ Non-GAAP EPS CAGR 13% 9% 11 Portfolio transformation Entrepreneurial Bruker Management Process Improved productivity ■ Shared services centers Enhanced compliance & risk management ■ 2012-18 ■ 2018-23G 2018-2022 ■ 2021-202X: PROJECT ACCELERATE 2.0 & OPERATIONAL EXCELLENCE Major focus Proteomics and Spatial Biology Microbiology & Molecular DX ■ ■ ROIC >20% ■ ■ BRUKER Biopharma & Applied, Semi Metrology Aftermarket, Consumables & Software Further improved productivity, tax rate, FCF Innovation with Integrity June 15, 2023 I 9